Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (JPRN-UMIN000058660) titled 'Real-world Outcomes in Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL) Treated with Epcoritamab in Japan' on Aug. 1.

Study Type: Observational

Study Design: Not selected Not selected

Primary Sponsor: Genmab US, Inc.

Condition: Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

Recruitment Status: Not Recruiting

Phase: Not selected

Date of First Enrollment: 2025/08/16

Target Sample Size: 300

Countries of Recruitment: Japan

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066647

Published by HT Digital Content Services with permi...